title: Effect of ezetimibe monotherapy on lipid metabolism and arterial stiffness assessed by cardio-ankle vascular index in type 2 diabetic patients.
abstract: OBJECTIVE
  High cholesterol absorption in the small intestine has been proposed to be a risk factor of atherosclerosis. In this study, we evaluated the effect of ezetimibe monotherapy on arterial stiffness in type 2 diabetic patients.
  
  
  METHODS
  Forty type 2 diabetes mellitus patients with high serum low-density lipoprotein cholesterol (LDL-C) were enrolled and treated with ezetimibe 10 mg/day for 6 months. HbA1c, serum lipids, remnant-like particle-cholesterol (RLP-C), serum lipoprotein lipase mass (LPL mass) and the cardio-ankle vascular index (CAVI) were measured before and after ezetimibe treatment.
  
  
  RESULTS
  After 6 months of ezetimibe treatment, significant decreases in LDL-C, RLP-C and CAVI were observed. In the group that achieved the LDL-C goal of <120 mg/dL after 6 months of ezetimibe treatment, the pretreatment CAVI was markedly high, and CAVI decreased significantly after ezetimibe treatment.
  
  
  CONCLUSIONS
  In type 2 diabetic patients, ezetimibe monotherapy may have the potential to ameliorate arterial stiffness in addition to lowering LDL-C and RLP-C.
authors.affiliation: Departments of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University, 564-1 Shimoshizu, Chiba, Japan. mumon@sf6.so-net.ne.jp
authors.forename: Yoh
authors.initials: Y
authors.lastname: Miyashita
authors.forename: Kei
authors.initials: K
authors.lastname: Endo
authors.forename: Atsuhito
authors.initials: A
authors.lastname: Saiki
authors.forename: Noriko
authors.initials: N
authors.lastname: Ban
authors.forename: Ayako
authors.initials: A
authors.lastname: Nagumo
authors.forename: Takashi
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Kawana
authors.forename: Daiji
authors.initials: D
authors.lastname: Nagayama
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ohira
authors.forename: Tomokazu
authors.initials: T
authors.lastname: Oyama
authors.forename: Kohji
authors.initials: K
authors.lastname: Shirai
mesh_terms: D000842:Ankle / Q000098:blood supply*; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001158:Arteries / Q000503:physiopathology*; D001384:Azetidines / Q000627:therapeutic use*; D001783:Blood Flow Velocity; D002318:Cardiovascular Diseases / Q000503:physiopathology*; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D000069438:Ezetimibe; D005260:Female; D006801:Humans; D050356:Lipid Metabolism; D008071:Lipoprotein Lipase / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D008078:Cholesterol, LDL; D008074:Lipoproteins; D014280:Triglycerides; C112017:remnant-like particle cholesterol; D002784:Cholesterol; D008071:Lipoprotein Lipase; D000069438:Ezetimibe